Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2014

View Archived Issues

Cleave Biosciences presents new lead compound CB-5083 for tumors

Phase II evaluation of an AT2 receptor antagonist for postherpetic neuralgia

TK-001, TK-002 and TK-003 to be outlicensed after phase Ib

LUTE and VERSE study data show efficacy for lebrikizumab in uncontrolled asthma

A first-in-class melanocortin MC4 receptor agonist for the treatment of sexual dysfunction

NDA for lubiprostone liquid formulation will not be filed this year

Five Prime Therapeutics and BMS sign collaboration for immuno-oncology therapies

Votrient receives an additional indication approval in Japan

Merck & Co. designs new agents for diabetes and other disorders

Amgen reports topline results from the phase III TESLA trial

Novel, selective 5-HT5A receptor antagonist as a potential treatment for schizophrenia

Allermist approved in Japan for pediatric allergic rhinitis

Treventis discloses novel agents for Alzheimer's disease

Boehringer Ingelheim synthesizes novel neutrophil elastase inhibitors

NVS-CRF38, a new CRF1 receptor antagonist, described by Novartis

Theracos reports data from phase II study of THR-1442 in type 2 diabetes

Researchers at Alios BioPharma present novel antiviral agents

NeoStem reports on fourth data safety monitoring board review of PreSERVE AMI trial

uniQure and Chiesi Farmaceutici report 6-year follow-up data for Glybera

Amorfix and Trellis Bioscience to collaborate on anti-CD38 cancer treatment

Cardium Therapeutics changes name to Taxus Cardium Pharmaceuticals

MD Anderson and MedImmune collaborate on cancer immunotherapy

ATL-1102 studied in phase I stem cell mobilization study

Resolve Therapeutics initiates clinical development of RSLV-132 for SLE

FDA approves Hemangeol for infantile hemangioma

FDA clears Summit to begin phase II study of SMT-19969 in C. difficile infection

SillaJen completes acquisition of Jennerex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...